To include your compound in the COVID-19 Resource Center, submit it here.

SCIO-469 p38 kinase inhibitor: Phase I

In a placebo-controlled, single-dose study of SCIO-469 in healthy

Read the full 91 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE